Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction—Outcomes at two years
Background: The registry-based randomized VALIDATE-SWEDEHEART trial (NCT02311231) compared bivalirudin vs. heparin in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI). It showed no difference in the composite primary endpoint of death, MI, or major bleeding at 180 days. Here, we report outcomes at two years. Methods: Analysis of primary and secondary endp